Biofreeze
Phase 3Small molecule
Biofreeze is one of 64 small molecule programs targeting Neck pain. It is currently in Phase 3.
3
Indications
5
Total Trials
1
Active Trials
63
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
56 competitors in Low Back Pain
#DrugCompanyPhaseTrials
1Cymbalta
Jazz PharmaceuticalsApproved
Aleve
Jazz PharmaceuticalsApproved
Voltaren
NovartisApproved
Advil
KKenvue Brands
Approved
Lioresal
NovartisApproved
Toradol
RocheApproved
Celebrex
PPhiladelphia Eye Associates
Approved
Oxycontin
PProtega
Approved
Bayer Aspirin
BayerApproved
MS Contin
HHikma Pharmaceuticals LLC
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Osteoarthritis2 trials
Low back pain1 trial
Biofreeze® vs. a Placebo on Chronic Low Back Pain Walking Gait Characteristics and Pain
Active, not recruiting·SSport and Spine Rehab Clinical Research Foundation·Phase 4·NCT03888820·20 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Biofreeze. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details